Investor Relations

Q2 2026

Corporate Overview

Download Presentation

Latest News

View All News
Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model
View All News

Latest Presentation

KPRX Q2 Corporate Deck
View All Presentations

Upcoming Event

Epilepsy Foundation Pipeline Conference

Add to Calendar View All Events

Company Overview

Kiora Pharmaceuticals (NASDAQ: KPRX) is a clinical-stage biopharmaceutical company developing advanced treatments for retinal disease. Our strategy is to target critical pathways underlying eye disease with innovative small molecules to preserve, slow, or restore vision loss.

View Executive Team

Latest Financial Results

Q1 2026

Quarter Ended Mar 31, 2026
View All Financial Results
Earnings Release
10-Q XBRL Zip

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2025

View 10-K

Stock Snapshot

IR Contacts

Headquarters

Kiora Pharmaceuticals, Inc.
169 Saxony Rd
Suite 212
Encinitas, CA 92024

Investor Relations

investors@kiorapharma.com